The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2018 | Highlights from ASH 2018: answering questions on combination therapies and screening strategies
Frank Griesinger, MD, PhD, of the University of Göttingen, Göttingen, Germany, discusses the unmet needs of current immunotherapy and chemotherapy combination approaches, raising important questions on their applications in second-line treatment. From the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany, Prof. Griesinger also discusses the future of effective screening in Europe, referring to current efforts towards the implementation of an operative screening strategy.
